<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980603</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-296</org_study_id>
    <nct_id>NCT00980603</nct_id>
  </id_info>
  <brief_title>Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of docetaxel alone, docetaxel plus
      cisplatin, and docetaxel plus S-1 in patients with metastatic gastric cancer after failing
      1st line chemotherapy with cisplatin plus S-1 or capecitabine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the most commonly used first-line chemotherapies have been based on fluorouracil
      and/or cisplatin in patients with metastatic gastric cancer. Unfortunately, considerable
      proportions of patients with metastatic gastric cancer do not respond to first-line
      chemotherapy and most of the patients who do respond eventually experience disease
      progression. In the second-line treatment, however, standard therapies are less clearly
      defined.

      Meanwhile, regarding re-challenge of previous failed drugs as a combination with an other
      newly introduced chemotherapeutic agent, there are few data. Increased expression and
      activity of thymidylate synthase, which is inhibited by fluoropyrimidine, is regarded to be
      the main reason for the development of clinical resistance to fluoropyrimidine. Since the
      cotreatment of docetaxel and 5-fluorouracil decreases the activity and expression of
      thymidylate synthase and dihydropyrimidine dehydrogenase (5-fluorouracil degradation enzyme),
      and increases the expression of orotate phosphoribosyl transferase, the addition of docetaxel
      into S-1 may recover the sensitivity to S-1 in patients previously resistant to S-1.

      Several reports found that MDR-1 and MRP-1 are related to cisplatin-resistance; cisplatin
      induces the overexpression of MRP-1, which reduces intracellular cisplatin accumulation.
      Since docetaxel suppresses the cisplatin-induced MRP-1 upregulation, the addition of
      docetaxel into cisplatin may recover the sensitivity to cisplatin in patients previously
      resistant to cisplatin.

      Based on these synergism mechanisms, we speculate that the cotreatment of docetaxel and
      cisplatin or S-1 has better anti-tumor activity than docetaxel alone in patients resistant to
      cisplatin or S-1.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>every 2 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>doctaxel plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cisplatin</intervention_name>
    <description>docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>doctaxel plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, S-1</intervention_name>
    <description>docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>docetaxel plus S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed gastric adenocarcinoma with metastatic
             disease

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  At least one measurable lesion as defined by RECIST

          -  Only one prior chemotherapy containing both S-1 or capecitabine and cisplatin for
             metastatic gastric cancer with documented progression of disease occurring during
             chemotherapy or within 6 months of completion of chemotherapy

          -  Adequate major organ function:

        ANC ≥1,500/mm3, Platelet ≥100,000/mm3, serum bilirubin ≤1.5 x upper limit of normal (ULN),
        AST/ALT ≤2.5 x ULN (≤5 x ULN if liver metastases are present), creatinine clearance ≥50
        ml/min using the calculation formula or 24 hours urine collection

          -  Patients should sign a written informed consent before study entry

        Exclusion Criteria:

          -  Prior taxane treatment

          -  Major surgery or radiotherapy less than 4 weeks prior to entry

          -  NCI CTCAE (version 3.0) adverse events ≥grade 2 except alopecia, fatigue, and weight
             loss

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome, or inability to take oral medication

          -  Patients with active gastrointestinal bleeding

          -  Inadequate cardiovascular function

          -  Serious concurrent infection or nonmalignant illness that is uncontrolled or whose
             control may be jeopardized by complications of study therapy

          -  Other malignancy within the past 3 years except adequately treated non-melanomatous
             skin cancer, carcinoma in situ of the cervix, or in situ of prostate cancer Gleason≤7

          -  Psychiatric disorder that would preclude compliance

          -  Patients receiving a concomitant treatment with drugs interacting with S-1 such as
             flucytosine, phenytoin, or allopurinol

          -  Female patients who are pregnant or breast feeding or adults of reproductive potential
             not employing effective method of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute and Hospital, National Cancer Center Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sook Ryun Park, Dr.</last_name>
    <phone>82-31-920-1609</phone>
    <phone_ext>1609</phone_ext>
    <email>sukryun73@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Lan Park, CRC</last_name>
    <phone>82-31-920-0422</phone>
    <phone_ext>0422</phone_ext>
    <email>lan0729@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chonju</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-Suk Han, M.D.</last_name>
      <email>sook3529@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hye-Suk Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute and Hospital, National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D.</last_name>
      <phone>82-31-920-1609</phone>
      <phone_ext>1609</phone_ext>
      <email>sukryun73@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Young Lan Park, RN</last_name>
      <phone>82-31-920-0422</phone>
      <phone_ext>0422</phone_ext>
      <email>lan0729@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Sook Ryun Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noe Kyeong Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngiee Park, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Nam, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Inchon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Bok Shin, M.D., Ph.D.</last_name>
      <email>dbs@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Dong Bok Shin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Jin Sym, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Wook Lee, M.D., Ph.D.</last_name>
      <email>hmodoctor@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Keun-Wook Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park/Dr.</name_title>
    <organization>Research Institute and Hospital, National Cancer Center</organization>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>S-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

